{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:27:09Z","timestamp":1740108429310,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00296-018-4115-0","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T13:30:07Z","timestamp":1532698207000},"page":"1825-1831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2458-5918","authenticated-orcid":false,"given":"Haruki","family":"Sawada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2036-6216","authenticated-orcid":false,"given":"Masei","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5966-6403","authenticated-orcid":false,"given":"Ryo","family":"Rokutanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-2088","authenticated-orcid":false,"given":"Daiki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Kishimoto","family":"Mitsumasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1798-0442","authenticated-orcid":false,"given":"Masato","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"key":"4115_CR1","first-page":"S77","volume":"22","author":"HB Townsend","year":"2004","unstructured":"Townsend HB, Saag KG (2004) Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 22:S77\u2013S82","journal-title":"Clin Exp Rheumatol"},{"key":"4115_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/bmj.316.7134.811","volume":"316","author":"PC G\u00f8tzsche","year":"1998","unstructured":"G\u00f8tzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811\u2013818","journal-title":"BMJ"},{"key":"4115_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"4115_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/13543784.12.4.673","volume":"12","author":"P Emery","year":"2003","unstructured":"Emery P (2003) The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 12:673\u2013681","journal-title":"Expert Opin Investig Drugs"},{"key":"4115_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 144:865\u2013876","journal-title":"Ann Intern Med"},{"key":"4115_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker J-C, Schiff M et al (2005) Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor \u03b1 Inhibition. N Engl J Med 353:1114\u20131123","journal-title":"N Engl J Med"},{"key":"4115_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M et al (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547\u2013554","journal-title":"Ann Rheum Dis"},{"key":"4115_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492\u2013509","journal-title":"Ann Rheum Dis"},{"key":"4115_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2007.083188","volume":"68","author":"C Salliot","year":"2008","unstructured":"Salliot C, Dougados M, Gossec L (2008) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68:25\u201332","journal-title":"Ann Rheum Dis"},{"key":"4115_CR10","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD008794.pub2"},{"key":"4115_CR11","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/acr.21654","volume":"64","author":"PS Kim","year":"2012","unstructured":"Kim PS, Ho GY, Prete PE, Furst DE (2012) Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 64:1265\u20131268","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4115_CR12","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/art.22750","volume":"56","author":"CL Bigbee","year":"2007","unstructured":"Bigbee CL, Gonchoroff DG, Vratsanos G et al (2007) Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 56:2557\u20132565","journal-title":"Arthritis Rheum"},{"key":"4115_CR13","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096\u20131103","journal-title":"Ann Rheum Dis"},{"key":"4115_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R et al (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86\u201394","journal-title":"Ann Rheum Dis"},{"key":"4115_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"4115_CR16","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/ard.2008.099218","volume":"68","author":"M Schiff","year":"2009","unstructured":"Schiff M, Pritchard C, Huffstutter JE et al (2009) The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 68:1708\u20131714","journal-title":"Ann Rheum Dis"},{"key":"4115_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.autrev.2008.11.003","volume":"8","author":"R Caporali","year":"2009","unstructured":"Caporali R, Pallavicini FB, Filippini M et al (2009) Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8:274\u2013280","journal-title":"Autoimmun Rev"},{"key":"4115_CR18","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/ard.2010.140129","volume":"70","author":"HC Leffers","year":"2011","unstructured":"Leffers HC, Ostergaard M, Glintborg B et al (2011) Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70:1216\u20131222","journal-title":"Ann Rheum Dis"},{"key":"4115_CR19","doi-asserted-by":"publisher","first-page":"e000040","DOI":"10.1136\/rmdopen-2014-000040","volume":"1","author":"A Finckh","year":"2015","unstructured":"Finckh A, Neto D, Iannone F et al (2015) The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open 1:e000040\u2013e000040","journal-title":"RMD Open"},{"key":"4115_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/RHU.0000000000000469","volume":"23","author":"IM Jensen Hansen","year":"2017","unstructured":"Jensen Hansen IM, Asmussen Andreasen R, Van Bui Hansen MN, Emamifar A (2017) The reliability of disease activity score in 28 joints-c-reactive protein might be overestimated in a subgroup of rheumatoid arthritis patients, when the score is solely based on subjective parameters: a cross-sectional, exploratory study. J Clin Rheumatol 23:102\u2013106","journal-title":"J Clin Rheumatol"},{"key":"4115_CR21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/rheumatology\/keh322","volume":"43","author":"BF Leeb","year":"2004","unstructured":"Leeb BF, Andel I, Sautner J et al (2004) The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology 43:1504\u20131507","journal-title":"Rheumatology"},{"key":"4115_CR22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3899\/jrheum.121288","volume":"40","author":"A Weaver","year":"2013","unstructured":"Weaver A, Troum O, Hooper M et al (2013) Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol 40:1275\u20131281","journal-title":"J Rheumatol"},{"key":"4115_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR et al (2011) High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70:785\u2013791","journal-title":"Ann Rheum Dis"},{"key":"4115_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/ard.2005.038638","volume":"65","author":"JAP Silva Da","year":"2006","unstructured":"Da Silva JAP, Jacobs JWG, Kirwan JR et al (2006) Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65:285\u2013293","journal-title":"Ann Rheum Dis"},{"key":"4115_CR25","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/art.22070","volume":"54","author":"M Weinblatt","year":"2006","unstructured":"Weinblatt M, Combe B, Covucci A et al (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54:2807\u20132816","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4115-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T18:33:37Z","timestamp":1720463617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4115-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4115"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4115-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"20 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MK received honoraria from Ono Pharm Co Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the St. Luke\u2019s International Hospital Ethics Committee institutional review board (approval number: 17-R026) and was carried out in accordance with the ethical principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}